N@N

Market Maker Surveillance Report. CBM, CLRO, RGDX, PSPW, VICL, DSCO, Winning Stocks With Lowest Price Friction For Thursday, M

May 12, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 2616 companies with "abnormal" market making, 2784 companies with positive Friction Factors and 1959 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. CAMBREX CORP (NYSE:CBM), CLEARONE COMMUNICATIONS INC (NASDAQ:CLRO), RESPONSE GENETICS INC (NASDAQ:RGDX), PRIME SUN POWER INC (OTCBB:PSPW), VICAL INC (NASDAQ:VICL), DISCOVERY LABORATORIES INC (NASDAQ:DSCO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     CBM        $0.910       20.18%       90,613          47.91%       49,125          25.97%       41,488          456     
     CLRO       $1.660       26.39%       65,727          62.28%       39,504          37.43%       26,223          158     
     RGDX       $0.540       28.57%       51,450          59.98%       34,227          39.90%       17,223          319     
     PSPW       $0.840       97.67%       355,255         45.70%       141,004         18.14%       214,251         2,551   
     VICL       $0.920       23.29%       1,561,027       56.86%       1,174,195       42.77%       386,832         4,205   
     DSCO       $0.520       23.96%       4,448,135       54.77%       3,663,258       45.10%       784,877         15,094  

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows CBM with a dollar gain Thursday of $0.91000 and a Friction Factor of 456 shares. That means that it only took 456 more shares of buying than selling to move CBM higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

CAMBREX CORP (NYSE:CBM) - Cambrex Corporation, a life sciences company, provides products and services for the development and commercialization of new and generic therapeutics. Its products include active pharmaceutical ingredients and pharmaceutical intermediates for use in the production of prescription and over-the-counter drug products, and other custom chemicals derived from organic chemistry. The company sells its products through sales agents and independent agents to pharmaceutical and generic drug companies worldwide. Cambrex Corporation was founded in 1981 and is based in East Rutherford, New Jersey.

CLEARONE COMMUNICATIONS INC (NASDAQ:CLRO) - ClearOne Communications, Inc. operates as a communications solutions company that develops and sells audio conferencing, collaboration, streaming media, and connectivity systems and other related products for audio, video, and Web applications. It develops, manufactures, markets, and services a line of audio conferencing products under personal, tabletop, premium, and professional (installed audio) categories. The company, through its subsidiary, NetStreams, Inc., delivers the Internet protocol (IP) A/V experience by distributing high definition (HD) audio and video over TCP/IP networks. Its digital streaming media and control systems support virtually various digital or analog sources, including high definition audio and video content to an unlimited number of networked end points. NetStreams StreamNet technology provides solutions for streaming media and control applications, such as digital signage, distribution of HD video and audio, LAN Cloud Matrix Switching, and audio paging over data networks. The companys conferencing and collaboration products are used by organizations of all sizes to accomplish group communication; and networked media and control distribution systems are used by a range of customers from individual residential users to large enterprises. Its end-users include large companies and institutions, small and medium sized businesses, educational institutions, and government organizations, as well as individual consumers. The company sells its products to end-users primarily through a network of independent distributors and resellers, as well as directly to dealers, systems integrators, value-added resellers, and end-users. ClearOne Communications, Inc. was founded in 1983 and is headquartered in Salt Lake City, Utah.

RESPONSE GENETICS INC (NASDAQ:RGDX) - Response Genetics, Inc., a life sciences company, engages in the research, development, marketing, and sale of clinical diagnostics and pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and Japan. It offers ResponseDX: Lung test suites for non-small cell lung cancer; ResponseDX: Colon test suites for colorectal cancer; and ResponseDX: Gastric test suites for gastric and gastroesophageal cancer. The companys Response DX test measures the RNA expression of ERCC1, TS, and RRM1 through reverse transcription polymerase chain reaction analysis from a patient's tumor tissue; and polymerase chain reaction analysis of DNA from the patient's sample to determine EGFR amplification, as well as BRAF, EGFR, and KRAS mutational status. It is also developing tests for other types of cancer that identify genetic profiles of tumors that recur after surgery. The company offers its products through its sales force to community based oncologists, hospitals, and physician offices. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

PRIME SUN POWER INC (OTCBB:PSPW) - Prime Sun Power Inc. focuses on the development, construction, and operation of utility-scale photovoltaic power plants. It intends to generate photovoltaic solar power in Europe, primarily in Italy, Greece, and Turkey. The company was formerly known as ATM Financial Corp. and changed its name to Prime Sun Power Inc. in April 2008. Prime Sun Power Inc. was founded in 2002 and is based in New York, New York.

VICAL INC (NASDAQ:VICL) - Vical Incorporated engages in the research and development of biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its products include Allovectin-7 immunotherapeutic, a Phase III clinical trial product to treat metastatic melanoma; TransVax, a Phase II clinical trial product to prevent viral reactivation and disease after transplant; Prophylactic vaccine for H5N1 pandemic influenza virus, which completed Phase I clinical trial to protect against infection, disease, and/or viral shedding; Prophylactic vaccine for H1N1 pandemic influenza virus, which is under preclinical trial to protect against infection, disease, and/or viral shedding; CyMVectin prophylactic vaccine for cytomegalovirus, which is under preclinical trial to prevent infection before and during pregnancy; and Therapeutic vaccine for herpes simplex type 2 virus, which is under research to prevent recurring flare-ups. The company, through corporate collaborations, develops Collategene angiogenic therapy encoding Hepatocyte Growth Factor, Temusi angiogenic therapy encoding Fibroblast Growth Factor 1, and Angiogenic therapy encoding Hepatocyte Growth Factor to induce local growth of blood vessels to restore blood flow to limbs and heart affected by ischemia; Therapeutic vaccine encoding human telomerase reverse transcriptase to treat non-small cell lung, prostate cancer, melanoma, or carcinomas of the upper GI tract, colon, kidney, or bladder; Prophylactic and/or therapeutic hepatitis C vaccine to protect farm-raised salmon from infection; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to increase survival time of dogs with oral melanoma. Vical Incorporated, through government collaboration, develops Prophylactic and/or therapeutic HIV vaccine to prevent/treat infection or disease. The company was founded in 1987 and is based in San Diego, California.

DISCOVERY LABORATORIES INC (NASDAQ:DSCO) - Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant therapies to treat respiratory disorders and diseases based on its KL4 surfactant and capillary aerosol-generating technologies. Its development stage products include Surfaxin, a synthetic, peptide-containing surfactant in phase III clinical trial for the prevention of respiratory distress syndrome in premature infants; Surfaxin LS, a Phase III trial product to improve ease of use for healthcare practitioners; and Aerosurf, an aerosolized KL4 surfactant that has completed first pilot Phase II clinical trial for the treatment of respiratory distress syndrome in premature infants. The company has a license agreement with Philip Morris USA Inc. to use its capillary aerosolization technology for use with pulmonary surfactants for the respiratory diseases and conditions; and a strategic alliance agreement with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net